Johnson & Johnson (JNJ) has demonstrated improving relative strength within the Favored Green Zone of the SIA S&P 100 Index Report. The shares currently hold an SIA SMAX score of 9 out of 10 and rank 13th out of 103 securities in the report. Johnson & Johnson has advanced 6 positions over the past month and 25 positions over the past quarter.
The Drugs sector is positioned in the Favored Green Zone of the SIA Sector Report, ranking 2nd out of 31 sectors. The sector has advanced 1 position over the past month and 14 positions over the past quarter.
Johnson & Johnson’s most recent Point and Figure signal is a Double Top. The shares recently moved above previous resistance at $267.49. Potential resistance based on Point and Figure measured-move methodology is located at $289.54, followed by $313.41. On a pullback, initial support is located at the 3-box reversal level of $252.07, with additional support at $242.28.
The shares have gained 3.66% over the past month, 17.18% over the past quarter, and 33.40% year to date. By comparison, the iShares S&P 100 ETF (OEF) has gained 3.76%, 1.73%, and 10.41%, respectively, over the same periods.
Johnson & Johnson is a diversified global healthcare company operating through its Innovative Medicine and MedTech businesses. Innovative Medicine focuses on areas including oncology, immunology, neuroscience, cardiovascular, pulmonary hypertension, and infectious diseases. MedTech provides products and technologies across surgery, orthopaedics, cardiovascular care, and vision. The company no longer operates a consumer-health division following the separation of Kenvue.
Disclaimer: SIACharts Inc. specifically represents that it does not give investment advice or advocate the purchase or sale of any security or investment whatsoever. This information has been prepared without regard to any particular investors investment objectives, financial situation, and needs. None of the information contained in this document constitutes an offer to sell or the solicitation of an offer to buy any security or other investment or an offer to provide investment services of any kind. As such, advisors and their clients should not act on any recommendation (express or implied) or information in this report without obtaining specific advice in relation to their accounts and should not rely on information herein as the primary basis for their investment decisions. Information contained herein is based on data obtained from recognized statistical services, issuer reports or communications, or other sources, believed to be reliable. SIACharts Inc. nor its third party content providers make any representations or warranties or take any responsibility as to the accuracy or completeness of any recommendation or information contained herein and shall not be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. Any statements nonfactual in nature constitute only current opinions, which are subject to change without notice.
